Overview

New approach for drug repurposing represents drug discovery and development which is a tedious process that requires 10-15 years of time, investments up to $1-2 billion, and have high risk of failure to enter into market for clinical applications. As the drugs has to pass through number of developmental phase, the likelihood for a drug to be approved from phase I clinical trial to United States of Food and Drug Administration (USFDA) approval is less than 10%. More than 90% of drugs failed in due to toxicity, efficacy and clinical trials. Drug repurposing is one of the roadway to accelerating drug discovery and development for treating disease and thus to providing better quality of life. This volume covers an overview of drug repurposing, novel methods, mechanism of action, lab on chip for drug repurposing, computational biology, system biology, artificial intelligence and machine learning for drug repurposing, target identification, target mining, high throughput drug screening, clinical trial of repurposed drug, repurposed biologics, and regulatory consideration and intellectual property right of repurposed drug. This volume highlights a number of aspects of the drug repurposing that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest.

Full Product Details

9780443223389

Table of Contents

Reviews

Author Information

Dr Vijai Singh is a Professor and Dean (Research & Innovation) at School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. He was an Associate Professor in the Department of Biosciences, School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. Prior this this, he was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, India and also an Assistant Professor in the Department of Biotechnology at the Invertis University, Bareilly, India. Prior to that, he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He received his Ph.D. in Biotechnology from the National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on building novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally, his laboratory is working on CRISPR-Cas9 tools for genome editing. He has more than 11 years of research and teaching experience in synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has published 100 articles, 70 chapters, 15 books and 3 patents. He serves as an associate editor, editorial board member, and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available